Physician profile
Erin Rizzo
NPI 1912429051
$3,440.58
in general payments reported to CMS, 2019-2025
16 companies · $579 in 2025
The $579 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $202 · 2023: $444 · 2024: $2,085 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,166 · Travel and Lodging: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.15 |
| Travel and Lodging | $941.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,607.85 | 2022-2025 | Symplicity G3 |
| Heartflow, INC. | $274.96 | 2024-2025 | |
| Abbott Laboratories | $229.96 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $201.45 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $176.69 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $168.50 | 2022-2025 | Repatha, Repatha |
| Cardiac Dimensions, INC. | $142.67 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.41 | 2023-2024 | Jardiance |
| Pfizer INC. | $95.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $95.14 | 2022-2025 | Farxiga, Wainua |
| Alnylam Pharmaceuticals INC. | $93.99 | 2023-2025 | Amvuttra, Onpattro |
| Scpharmaceuticals INC. | $83.07 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $46.88 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.37 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $37.44 | 2022-2023 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Rizzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.